Top Markets
#1 GEKKO GEKKO +52.86%
#2 Helium Helium +48.09%
#3 Pons Pons +29.16%
#4 龙虾 (Lobster) 龙虾 (Lobster) +18.73%
#5 ADO Protocol ADO Protocol +18.06%
#6 Main Street Yield Main Street Yield +17.48%
#7 Collect on Fanable Collect on Fanable +16.65%
#8 OpenGradient OpenGradient +12.52%
#9 o1.exchange o1.exchange +12.13%
#10 Nillion Nillion +10.62%
Coin of the day
GEKKO GEKKO
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Corvus Pharmaceuticals, Inc. Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc.

CRVS
Classement en actions #8729
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Prix de l'action
$14.07
Dernière synchronisation: 2026-08-28
Capitalisation boursière
$1.18B
Changement (1 jour)
-4.41%
Changement (1 an)
145.13%
Pays
US
Échange Corvus Pharmaceuticals, Inc. (CRVS)

Catégorie

Healthcare
Revenus pour Corvus Pharmaceuticals, Inc. (CRVS)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de Corvus Pharmaceuticals, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Corvus Pharmaceuticals, Inc. de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH